Payment Expenses. Debtor agrees to pay all reasonable attorneys’ fees of Lender in connection with the drafting and execution of this Amendment.
Payment Expenses. Buyer shall bear all expenses and bank charges in connection with any payments made to Seller under this Agreement, including, without limitation, any costs of establishing and obtaining confirmation of a Letter of Credit referred to in Article 7.3.
Payment Expenses. Client agrees to pay Consultant in accordance with the terms and conditions set forth in this Agreement and the executed Exhibit(s). Client will not be obligated to reimburse Consultant for any expenses paid or incurred by Consultant except as set forth in the executed Exhibit(s), or as otherwise approved in writing by Client and Consultant.
Payment Expenses. 6.3.1 All payments under this Article 6 shall be made by wire transfer of immediately available funds to a bank account designated in writing by Catalyst.
6.3.2 Each Party shall bear its own costs and expenses associated with its responsibilities under this Agreement, except as expressly set forth in this Agreement. Any amounts payable under this Agreement which are not paid within thirty (30) days of their due date shall bear interest at a rate equal to [***] percent ([***]%) per annum, which shall be computed on the basis of a 365 day year.
Payment Expenses. During the Term of this Agreement, Augmedix agrees to provide the Services described or listed on the attached Exhibit A, and Sutter agrees to purchase such Services at the fees indicated in Exhibit A and in accordance with the terms and conditions set forth herein. As of the Fourth Amendment Effective Date, Augmedix will directly invoice the respective foundation or subsidiary of Sutter for Implementation Fees for each New Authorized User upon Service Order execution, and for monthly service fees [*] prior to the applicable month of service. All invoices will be subject to [*] payment terms after receipt of accurate invoices from Augmedix. Sutter may, at its discretion, make payment by check or by an electronic payable (E-payables) payment method. Other than as stated in this Agreement, any Exhibit, or as subsequently agreed to in writing between the Parties, Augmedix is solely responsible for payment of any other expenses incurred in connection with carrying out Augmedix’s duties under this Agreement. Such expenses include costs of all travel, lodging, food, licenses, bonds, taxes and costs of doing business. In no event will Sutter be responsible to pay any expenses of Augmedix not contained in this Agreement or as otherwise agreed to in writing between the Parties, whether or not incurred in connection with Augmedix’s performance under this Agreement. To the extent that billing category changes result in an overpayment or underpayment of Fees for the applicable invoice period, Augmedix will reconcile any credits owed to, or additional amounts owed by, Sutter against any prepaid amounts on a quarterly basis. The parties shall agree to any amounts owed to, or by, Sutter, in writing, prior to making such billing adjustment. In the event that Service for a particular Authorized User has not been prepaid, Augmedix shall apply any credits owed to, or additional amounts owned by, Sutter against the earliest subsequent invoice. Additionally, in the event that Sutter prepaid for any Service and the Service is cancelled in accordance with Section 1.1.3 of Exhibit A of the Agreement, any remaining prepayment balance will be credited towards payment for another Authorized User within [*] of the effective date of termination.
2. Exhibit B (Definitions). The following terms shall be added to the definitions set forth in Exhibit B:
Payment Expenses. 5.3.1. The Fee is due and payable in advance, upon the effective date of this Agreement.
5.3.2. The Commission is due and payable 10 days after the payment of any amount to the Talent under a relevant contract.
5.3.3. The Fee and the Commission shall be paid in Swiss francs and include the reimbursement of all expenses incurred by Basketball Dream in the performance of any services provided under this Agreement.
Payment Expenses. During the Term of this Agreement, Augmedix agrees to provide the Services described or listed on the attached Exhibit A, and Sutter agrees to purchase such Services at the fees indicated in Exhibit A and in accordance with the terms and conditions set forth herein. Beginning June 1, 2015, Augmedix will directly invoice the respective foundation or subsidiary of Sutter receiving Services [*] prior to the applicable fees; all invoices will be subject to [*] payment terms after receipt of accurate invoices from Augmedix. Notwithstanding the foregoing, Augmedix shall invoice Sutter on April 15, 2015, for all applicable fees incurred by Sutter between May 1, 2015 to September 31, 2015 under the Agreement. Sutter may, at its discretion, make payment by check or by an electronic payable (E- payables) payment method. Other than as stated in this Agreement, any Exhibit or as subsequently agreed to in writing between the Parties, Augmedix is solely responsible for payment of any other expenses incurred in connection with carrying out Augmedix’s duties under this Agreement. Such expenses include costs of all travel, lodging, food, licenses, bonds, taxes and costs of doing business. In no event will Sutter be responsible to pay any expenses of Augmedix not contained in this Agreement or as otherwise agreed to in writing between the Parties, whether or not incurred in connection with Augmedix’s performance under this Agreement.
Payment Expenses. (a) Anthra shall pay to Leiras, for the rights and license granted under this Development Agreement, a nonrefundable payment of Three Million Five Hundred Thousand Dollars ($3,500,000), as follows:
(i) One Million Dollars ($1,000,000) on or before the Effective Date of this Development Agreement of which Leiras acknowledges receipt of Two Hundred Thousand Dollars ($200,000) in accordance with the Option Agreement dated July 6, 1998; and
(ii) Two Million Five Hundred Thousand Dollars ($2,500,000) on the earlier of (i) thirty (30) days after the pre-NDA meeting between representatives of Anthra and the FDA and (ii) December 31, 1998.
(b) Subject to the foregoing payments, and, except as provided in Section 5.6 hereof, no royalty shall be payable by Anthra to Leiras for the right and licenses granted to Anthra under this Development Agreement.
(c) All payments to be made by Anthra to Leiras under this Development Agreement shall be made in United States Dollars and shall be made by wire transfer to such bank account as shall be specified in writing five (5) days in advance by Leiras.
(d) Anthra shall pay to the proper taxing authority any and all withholding taxes or similar charges imposed by any governmental unit in the Territory on any amounts due to Leiras from Anthra pursuant to this Section 5, and shall use commercially reasonable efforts to obtain and send to Leiras proof of such payment of such taxes or charges. All amounts paid by Anthra pursuant to this 28 Section 5.4 shall be paid for the account of Leiras and deducted from the amounts due from Anthra to Leiras pursuant to this Section 5.
(e) The compensation for Leiras' services in conducting the Additional Studies shall be FIM 3.100 per person day on each day exceeding 10 person days plus all direct out-of-pocket costs (which compensation does not include any financial costs or general and administrative costs). Further, in the event Anthra requests Leiras' assistance in clinical or regulatory matters, Anthra shall pay Leiras a compensation of FIM 3.100 per person day plus direct outside costs, however, Leiras shall not be requested to provide more than ten (10) person days of such assistance to Anthra. The above mentioned daily compensation of FIM 3.100 is valid as of the Effective Date and will be increased annually by a cost increase, if any, due to collective bargaining agreements, as applied customarily by Leiras.
(f) If Anthra grants any third party any rights to Market, distribute or sell ...
Payment Expenses. (a) ELEVAI shall pay all royalties accruing to Yuva Bio in U.S. Dollars, without deduction of exchange, collection, wiring fees, bank fees, or any other charges, within thirty (30) days following the calendar quarter in which Net Sales occur.
(b) All payments shall be made by wire transfer of immediately available funds to a bank account designated in writing by the recipient Party.
(c) For converting any Net Sales made in a currency other than United States Dollars, the parties will use the conversion rate published in the Wall Street Journal conversion rate reported by the Chase Manhattan Bank (N.A.), or other industry standard conversion rate approved in writing by Yuva Bio for the last day of the calendar quarter for which such royalty payment is due or, if the last day is not a business day, the closest preceding business day.
(d) If at any time legal restrictions prevent the prompt remittance of part or all of any royalties with respect to any country in the Licensed Territory where any Licensed Product is sold, payment shall be made through such lawful means or method as the parties reasonably shall determine, the parties agreeing to fully cooperate in effecting such remittance.
(e) Each Party shall bear its own costs and expenses associated with its responsibilities under this Agreement, except as expressly set forth in this Agreement.
Payment Expenses. The Client will pay Performance Fact a total of $105,000 for professional services for the 2022-2023 school year, according to the estimates and scope of work outlined in Exhibit A. The amount will cover fees for professional services and expenses associated with the project, including, development and compilation of presentation materials and ongoing communication with the Superintendent, and with the Board and other stakeholders, as outlined in the Exhibits. Scope of work and professional fees associated with the implementation of the Strategic Plan during 2022-2023 SY and/or future school years are not included in this Agreement. Actual scope and fees for future year(s) will be agreed to by the Client, if the Client chooses Performance Fact as an implementation phase partner.
